Dr. Maggie De Block:

A university calculated that when we had the immunotherapy reimbursed much earlier, at a certain moment a few years ago we had already saved 9,000 life years for patients - it could be one year for one patient and ten years for another patient. There were different cancers to treat. For example, for melanoma, where people were already in stage 4 with metastatic symptoms, some have been in remission for years and they look like they have regained their life and also their quality of life. In life years, it was 9,000 after a year and a half.

Of course, once the immunotherapy was there, the early track was also for treating lung cancers and old cell cancers which previously could not be cured, as well as ovarian cancer. Once it was reimbursed, it was used as a third-line therapy for many cancers and then came the data that it helped and was okay, and, as I said, the train was there for many patients to be helped with that. I have much more information on that and I will send the answers to the committee.